The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis
Open accessAbstract
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules. Methods: We performed a systematic review of the literature databases like PubMed, Cochrane, Embase, and clinicaltrials.gov until November 2023. Data related to different doses of oral danuglipron and orforglipron and their gastrointestinal side effects including nausea, vomiting, constipation, diarrhea, eructation, and dyspepsia were obtained. Analysis was done using RevMan v5.4 (The Cochrane Collaboration, Copenhagen, Denmark). Results: We included a total of 4 studies of which 2 each were for danuglipron and orforglipron. The oral doses of orforglipron studied were 12 mg, 24 mg, 36 mg, and 45 mg, with nausea being the most common side effect in all groups. For the 45 mg dose of orforglipron, the odds ratio (OR) was 4.41 (95% CI: 2.90–6.71), while the 36 mg dose had an OR of 3.99 (95% CI: 2.22–7.18). The OR for the 24 mg dose was 5.66 (95% CI: 3.39–9.45), and the 12 mg dose showed an OR of 5.06 (95% CI: 3.31–7.73). Oral danuglipron at doses of 80 mg and 120 mg were also studied. The 120 mg dose of danuglipron had a pooled OR of 4.38 (95% CI: 2.30–8.34) while the 80 mg dose had an OR of 3.69 (95% CI: 1.77–7.67) indicating a significant decrease in gastrointestinal side effects. Conclusion: Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists were widely reported but less frequent compared to placebo/ standard treatment. There was no significant dose-dependent increase in the side effects of these medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These trials also highlighted that weight loss with orforglipron is not solely attributable to gastrointestinal side effects, as progressive reductions were observed after initial dose titration, and appetite suppression was corroborated by patient-reported satiety measures.”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“[11] The results’ statistical significance was verified with a 2-sided P -value of .05.”
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“[12] 3.”
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“[10] These studies were appraised by 2 researchers.”
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218 · cited 1×
“[9] Any disagreements are resolved by discussion or a third reviewer.”
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 3×
“[21] Acknowledging the high incidence of GI side effects like nausea and vomiting is critical for treatment adherence and patient quality of life.”
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723 · cited 2×
“[20,22] This highlights the importance of managing these side effects through dose adjustments, patient education, and potentially combining these agents with other medications to mitigate adverse effects.”
Research works printed but not linked: 1
- Lim, Glucagon-Like Peptide 1 Secretion by the L-Cell., Diabetes
Cited by
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a cornerstone in the management of T2D and obesity, providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, appetite reduction, and cardiometabolic benefits [17–23].”
Castro-Gamboa, J. A., Mora-Jiménez, J., Arguedas‐Chacón, S., & Zavaleta‐Monestel, E. (2026) · Cureus · doi:10.7759/cureus.110178
GLP-1-based multipharmacology: Biased signaling as a determinant of therapeutic efficacy
Li, W., Yan, J., Zhao, F., & Yang, D. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.07.001
Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities
Vahora, S., Shah, V., & Patel, B. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04185-2 · Cited by 2
“However, dose escalation increases local gastrointestinal exposure, contributing to nausea, vomiting, diarrhea, and dyspepsia, with pooled odds ratios for nausea ranging from 3.69 to 5.66 across oral GLP-1 receptor agonist doses [46].”
InfluentialSun, C., Zhu, K., Li, Y., Li, F., Zhang, Y., Wang, Z., Zhao, H., Wang, W., Zhang, X.-L., Zhang, W., et al. (2026) · Foods · doi:10.3390/foods15193378
Metadata
- Authors
- Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., Sah, R., Khanal, A., Ahmed, K., & McDonald, P.
- Affiliations
- Dubai Health Authority (AE)
- Tribhuvan University (NP)
- Reading Hospital (US)
- Saint Agnes Hospital (US)
- Hurley Medical Center (US)
- Department of Medicine, Frye Regional Medical Center, Hickory, NC
- St. John's Hospital (US)
- Boston Medical Center (US)
- Wake Forest University Health Sciences (US)
- Corresponding author
- Shah, Sangam
- ORCID
- Venue
- Medicine
- Published
- 2025-12-26
- Volume
- 104
- Issue
- 52
- Pages
- e46671
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC12746972
- OpenAlex
- W7117294626
- Cited by
- 5
- References
- 26
- Citations by year
- 2026: 5
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- GLP-1 receptor agonists, orforglipron, gastrointestinal adverse effects, nausea, vomiting, constipation, diarrhea, dyspepsia, eructation, dose-response relationship, oral administration, diabetes mellitus, weight loss, adverse drug reactions, pharmacokinetics, pharmacodynamics, pharmacovigilance
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Dose-Response Relationship, Drug, Gastrointestinal Diseases, Humans, Hypoglycemic Agents, Nausea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1097/md.0000000000046671
- The paper
- Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., Sah, R., Khanal, A., Ahmed, K., & McDonald, P. (2025). Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis. Medicine. https://doi.org/10.1097/md.0000000000046671
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.